Form 4: Guardant Health Executive Chris Freeman Reports Stock Option and Restricted Stock Unit Awards
SEC Form 4 Filing
Chris Freeman, Chief Commercial Officer of Guardant Health, reports the acquisition of stock options and restricted stock units.
Summary
- Chris Freeman, Chief Commercial Officer of Guardant Health, filed a Form 4.
- The filing reports the grant of stock options and restricted stock units on March 12, 2025.
- Freeman was granted options to purchase 23,145 shares of common stock at an exercise price of $43.10.
- These options vest over a three-year period, with 33% vesting on April 1, 2026, and the remaining 67% vesting in equal monthly installments over the subsequent two years.
- Freeman also received 15,430 restricted stock units (RSUs).
- These RSUs also vest over a three-year period, with 33% vesting on April 1, 2026, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.
- Following the reported transactions, Freeman directly owns 23,145 stock options and 15,430 restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management team. This is generally viewed positively.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology and healthcare industries, aligning management incentives with shareholder value creation.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
- Companies like Illumina, Exact Sciences, and Myriad Genetics also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules described are typical, with three-year vesting periods being common.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of earliest transaction (grant date of stock options and RSUs) |
| 03/12/2025 | Date of stock option award |
| 03/12/2025 | Date of restricted stock unit award |
| 03/13/2025 | Date of signature on the Form 4 filing |
| 04/01/2026 | First vesting date for 33% of both stock options and RSUs |
| 03/12/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.